EMICRO Biomedicine Company has obtained 3 international new drug PCT patents and has entered China (including Hong Kong (HK), the United States (US), Europe (EP), Canada (CA), Australia (AU), Japan (JP), South Korea (KR), etc.).

       The academic achievements, papers, and professional articles obtained by the Zhiwei research team have been published in multiple foreign journals and academic journals, including the American Journal of Medicinal Chemistry (JMC) and the European Journal of Medicinal Chemistry (EJMC).

       Special projects undertaken by the company: Major Science and Technology Projects in Xinxiang City in 2020 and 2021; Major Science and Technology Special Project of Henan Province in 2020 (completed); Major Project of Henan Province Industrial R&D Joint Fund in 2022 (Lymphoma Direction); Major Project of Henan Province Industrial R&D Joint Fund in 2024 (Autoimmune Disease Direction).